CARLSBAD, Calif.--(BUSINESS WIRE)--Centricity Vision, Inc., formerly known as Mynosys Cellular Devices, Inc., a global ophthalmic technology company dedicated to delivering products that help surgeons optimize outcomes in refractive surgery, today announced a new executive leadership team, along with a new company name.
“Centricity Vision” reflects the company’s core competency, embodied by its ZEPTO® Precision Cataract Surgery Platform, in creating precise, consistent, visual axis-centered capsulotomies. The new name also conveys the company’s evolution as it looks to expand its vision care product pipeline beyond ZEPTO® while remaining committed to improving cataract surgery outcomes for surgeons and their patients.
In addition to Rob Thornhill’s recent appointment as Chief Executive Officer, new executive team members include Louis Bunn, Chief Financial Officer; Todd Pinkney, Vice President of Marketing; Kevin Pratt, Vice President of Sales; Dan Glazerman, Vice President of Research, Development and Manufacturing; and Nealen Hartman, Vice President of Regulatory Affairs and Quality Assurance. This seasoned team leverages extensive experience in the ophthalmology and medical device industries to drive technological innovation, product quality and commercial success.
The company’s ZEPTO® Platform enables precise, reproducible, circular, visual axis-centered capsulotomies that facilitate a 360-degree overlap of the IOL optic. Published studies demonstrate the ZEPTO® capsulotomy edge was two to four times stronger than manual CCC and femtosecond laser capsulotomy.1 ZEPTO® not only automates the anterior capsulotomy, but also enables precise visual axis centration.2
“We have evolved significantly as a company, and we think it’s time our name did too,” said Rob Thornhill, President and CEO of Centricity Vision. “Building on our commitment to assisting surgeons in delivering the best care to their patients, our vision for the future includes leveraging our ZEPTO® technology to create a suite of next-generation ophthalmic capsular management products. I’m grateful for the opportunity to work with our new management team to deliver high-quality systems to our customers and their patients.”
ZEPTO® Precision Cataract Surgery Platform
The ZEPTO® Precision Cataract Surgery Platform enables consistent, visual axis-centered, high-quality anterior capsulotomies during cataract surgery. ZEPTO® integrates seamlessly into the routine steps of cataract surgery without increasing operative time or space requirements. The ZEPTO® platform consists of a disposable handpiece and a small, inexpensive control console. The ZEPTO® precision pulse capsulotomy technology utilizes a proprietary energy control algorithm to deliver a four-millisecond energy pulse, in combination with calibrated suction, to produce highly accurate, reproducible and strong-edged capsulotomies. ZEPTO® performs equally as well in standard or difficult cases and is ideal for cataract patients choosing premium or non-premium lenses.
ZEPTO® is available directly through the company’s sales and practice support team in the United States, as well as through select distributors in Europe and Asia. For more information, visit https://www.Zeptozone.com/ and follow the company on Twitter at @ZeptoCataracts.
About Centricity Vision, Inc.
Based in Carlsbad, Calif., Centricity Vision is a global ophthalmic technology company dedicated to providing surgeons with innovative solutions that enhance procedural excellence. Developer of the U.S. and internationally approved ZEPTO® Precision Cataract Surgery Platform, Centricity Vision is committed to providing high-quality, cost-effective solutions to assist physicians in delivering the best possible vision care to patients.
1 Thompson VM, Berdahl JP, Solano JM, Chang DF. Comparison of Manual, Femtosecond Laser, and Precision Pulse Capsulotomy Edge Tear Strength in Paired Human Cadaver Eyes. Ophthal. 2016 Feb;123(2):265-74.
2 Thompson V. Streamlined method for anchoring cataract surgery and intraocular lens centration on the patient’s visual axis. J Cataract Refract Surg. 2018 May;44(5):528-533.